StockData
ImmuCell Corp logo

ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.33−0.09 (-0.79%)

Close on Nov 17, 2026Market cap $102.90MP/E 141.6Yield –

ImmuCell price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

ImmuCell's price to book ratio was 2.9× on Nov 11, 2026, against 1.5× a year earlier. Over the last 5 years it ranged from 1.2× to 3.5×, with a median of 1.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.9×+1.1
2025Dec 31, 20251.9×+0.1
2024Dec 31, 20241.7×+0.2
2023Dec 29, 20231.5×+0.0
2022Dec 30, 20221.5×−0.4
2021Dec 31, 20211.9×+0.4
2020Dec 31, 20201.5×+0.3
2019Dec 31, 20191.3×−0.4
2018Dec 31, 20181.7×−0.4
2017Dec 29, 20172.1×+0.7
2016Dec 30, 20161.4×−0.9
2015Dec 31, 20152.3×+0.7
2014Dec 31, 20141.6×+0.2
2013Dec 31, 20131.4×+0.1
2012Dec 31, 20121.3×−0.2
2011Dec 30, 20111.5×+0.6
2010Dec 31, 20101.0×–

More ImmuCell figures

See a number that looks wrong?